Atossa Therapeutics (NASDAQ:ATOS) Price Target Raised to $7.00

Atossa Therapeutics (NASDAQ:ATOS) had its price target hoisted by HC Wainwright from $6.00 to $7.00 in a report published on Wednesday,Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Atossa Therapeutics’ FY2026 earnings at ($0.32) EPS, FY2027 earnings at ($0.27) EPS and FY2028 earnings at ($0.21) EPS.

ATOS has been the subject of a number of other reports. Ascendiant Capital Markets upped their price target on shares of Atossa Therapeutics from $6.25 to $6.50 and gave the company a “buy” rating in a report on Wednesday, September 11th. StockNews.com lowered shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, November 8th.

Atossa Therapeutics Stock Down 6.6 %

NASDAQ:ATOS opened at $1.28 on Wednesday. The company has a fifty day moving average of $1.44 and a 200 day moving average of $1.38. Atossa Therapeutics has a 52 week low of $0.65 and a 52 week high of $2.31. The firm has a market capitalization of $160.97 million, a P/E ratio of -5.82 and a beta of 1.23.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ATOS. Intech Investment Management LLC purchased a new stake in shares of Atossa Therapeutics in the 3rd quarter worth about $29,000. XTX Topco Ltd purchased a new stake in shares of Atossa Therapeutics in the 2nd quarter worth about $29,000. SG Americas Securities LLC grew its position in shares of Atossa Therapeutics by 254.3% in the 3rd quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock worth $64,000 after buying an additional 30,037 shares during the period. Cetera Advisors LLC purchased a new stake in shares of Atossa Therapeutics in the 1st quarter worth about $72,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Atossa Therapeutics in the 3rd quarter worth about $75,000. 12.74% of the stock is owned by hedge funds and other institutional investors.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.